Articles dans des revues avec comité de lecture (103)
  1. 73. Ghanem, G. E., & Journé, F. (2011). Tyrosinase related protein 1 (TYRP1/gp75) in human cutaneous melanoma. Molecular Oncology, 5(2), 150-155. doi:10.1016/j.molonc.2011.01.006
  2. 74. Herraiz, C., Journé, F., Abdel-Malek, Z., Ghanem, G. E., Jimenez-Cervantes Frigo, C., & Garcia-Borron, J. C. (2011). Signaling from the human melanocortin 1 receptor to ERK1 and ERK2 mitogen-activated protein kinases involves transactivation of cKIT. Molecular endocrinology, 25(1), 138-156. doi:10.1210/me.2010-0217
  3. 75. Id Boufker, H., Lagneaux, L., Najar, M., Piccart-Gebhart, M., Ghanem, G. E., Body, J.-J., & Journé, F. (2010). The Src inhibitor dasatinib accelerates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblasts. BMC cancer, 10, 298. doi:10.1186/1471-2407-10-298
  4. 76. Journé, F., Durbecq, V., Chaboteaux, C., Rouas, G., Laurent, G., Nonclercq, D., Sotiriou, C., Body, J.-J., & Larsimont, D. (2009). Association between farnesoid X receptor expression and cell proliferation in estrogen receptor-positive luminal-like breast cancer from postmenopausal patients. Breast cancer research and treatment, 115(3), 523-535. doi:10.1007/s10549-008-0094-2
  5. 77. Voorzanger-Rousselot, N., Journé, F., Doriath, V., Body, J.-J., & Garnero, P. (2009). Assessment of circulating dickkopf-1 with a new two-site immunoassay in healthy subjects and women with breast cancer and bone metastases. Calcified tissue international, 84(5), 348-354. doi:10.1007/s00223-009-9225-y
  6. 78. Dierickx, K. M. E., Journé, F., Gerbaux, P., Morandini, R., Kauffmann, J.-M., & Ghanem, G. E. (2009). Improving the spectrophotometric determination of the alkylating activity of anticancer agents: a new insight into the mechanism of the NBP method. Talanta, 77(4), 1370-1375. doi:10.1016/j.talanta.2008.09.015
  7. 79. Closset, J., Journé, F., Mboti, F., El Nakadi, I., & Gelin, M. (2008). Randomized controlled trial comparing somatostatin with octreotide in the prevention of complications after pancreatectomy. Hepato-gastroenterology, 55(86-87), 1818-1823.
  8. 80. Journé, F., Body, J.-J., Leclercq, G., & Laurent, G. (2008). Hormone therapy for breast cancer, with an emphasis on the pure antiestrogen fulvestrant: Mode of action, antitumor efficacy and effects on bone health. Expert opinion on drug safety, 7(3), 241-258. doi:10.1517/14740338.7.3.241
  9. 81. Journé, F., Durbecq, V., Haibe-Kains, B., Chaboteaux, C., Rouas, G., Laurent, G., Larsimont, D., Piccart-Gebhart, M., Body, J.-J., & Sotiriou, C. (2008). Farnesoid X receptor (FXR) status complements the evaluation of estrogen receptor alpha (ER) in breast cancer (BC) patients and predicts benefit from tamoxifen. European journal of cancer, 6(7), Suppl, Abstr 218 (EBCC-6), 112. doi:10.1016/S1359-6349(08)70534-2
  10. 82. Journé, F., Laurent, G., Chaboteaux, C., Nonclercq, D., Durbecq, V., Larsimont, D., & Body, J.-J. (2008). Farnesol, a mevalonate pathway intermediate, stimulates MCF-7 breast cancer cell growth through farnesoid-X-receptor-mediated estrogen receptor activation. Breast cancer research and treatment, 107(1), 49-61. doi:10.1007/s10549-007-9535-6
  11. 83. Journé, F., Durbecq, V., Chaboteaux, C., Rouas, G., Haibe-Kains, B., Id Boufker, H., Laurent, G., Sotiriou, C., Larsimont, D., & Body, J.-J. (2008). Farnesoid X receptor (FXR): A new marker for the prediction of bone metastases in breast cancer. Cancer treatment reviews, 34, Suppl. 1 , OC3 (CIBD-VII), 550.
  12. 84. Journé, F., Kheddoumi, N., Chaboteaux, C., Duvillier, H., Laurent, G., & Body, J.-J. (2008). Extracellular calcium increases bisphosphonate-induced growth inhibition of breast cancer cells. Breast cancer research, 10(1), R4. doi:10.1186/bcr1845
    13. << Précédent 1 2 3 4 5 6 7 8 9 10 Suivant >>